October/November #167 : From Mice Into Men - by Regan Hofmann with Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

From Mice Into Men

The Doctor Is In




At the End of Your Rope?

A Slippery Slope?

Senior Strength




POZ Q&A: Jeffrey Crowley

Standing Against Stigma

The Stigma Index

ADAP Update

Get Your Game On

It’s Everyone’s Business

Pozarazzi




Editor's Letter

Letters

No Hate



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

October / November 2010


From Mice Into Men

by Regan Hofmann with Tim Horn


Thankfully, the biotech and pharmaceutical industries stand to see a very healthy return on AIDS cure investments. In other words, finally, a cure may prove more profitable for them than a world of people on ARVs for the rest of their lives. And governments and insurance companies, which also bear the brunt of paying for HIV treatment, have a vested interest in heralding in a cure. One challenge is that the system itself is not set up to facilitate a cure for HIV. The same organizations (NIH) that fund basic biomedical research have no financial incentive to get a possible therapy to market. They are paid to discover the basic science, not develop it. And groups such as venture capital investment firms and pharmaceutical companies that could financially benefit from such development are shying away from investing in AIDS cure research, partly, because it has proved so expensive and challenging. One hope is that the epiphany that the global market for ARVs may not always prove lucrative may drive venture cap and pharmaceutical companies to get some skin in the cure game.

It is not sufficient to say, “Whoever finds the cure for AIDS will be rich.” Unless we spend enough money on the search, not enough people will look, and we will be less likely to find it. It takes a lot of money to look. And it takes a lot of money to get basic scientific discoveries translated into potential therapies that are ready to enter clinical trials and, if all goes well, get FDA approval. Consider this: The cost of researching and developing a single drug, from molecular discovery to pharmacy shelves, has been estimated as between $500 million and $2 billion—and that’s using the dollar value from a decade ago.

The AIDS Policy Project’s executive director Kate Krauss sums it up best: “We have a chance to dismantle this pandemic. What we do now as activists could determine whether the AIDS pandemic lasts another seven years—or 30—and who will outlive it. We need nine times more money than we have right now for scientists to pursue genuinely original ideas. We need to build a pipeline to test in people not just one or two treatments but a steady and growing list of potentially curative therapies. A workable cure may involve more than one approach, so collaboration—virologist-immunologist, Parisian-New Yorker—is critical. Researchers collaborate in real time in multiple sclerosis research, why not also with AIDS? New funding has to reward new ideas and real teamwork. Is the scientific world ready to promote and encourage another Gero Hütter? Not yet. But it should be. This [moment] is a rare opportunity for philanthropists to step up and do something pivotal in the history of the AIDS pandemic.”
 
In addition to awareness, advocacy, cash and scientific breakthroughs, we need to revolutionize the way we conduct AIDS research if we’re going to find the cure.

To create a bigger, bolder, more diverse pipeline, we need to put as many promising options for the cure into pilot studies within the next two years as possible. The days of five-year, three-country, 5,000-patient studies should be numbered. As long as we can establish legitimate baselines of safety, we should be able to forge ahead faster and more nimbly to get the answers millions desperately need. Let’s see some five-month, five-people trials. Researchers can no longer toil alone in their ivory towers, holding their ideas and discoveries close to their chests. We need to encourage openness and collaboration. We need to give people incentives to work together. And we need to share learning between groups along the way, not just when all is said and done—and published in medical journals. What about a centralized database of cure research projects, perhaps one that could allow researchers to share findings—and best practices—ideally mid-study?

We need to lure new talent from other areas of biomedical research (remember, the first man to perhaps technically cure AIDS was neither a virologist nor an immunologist). We need long-term, stable and flexible approaches to funding to allow scientists to focus on doing research, not applying for grants.

We need to better track AIDS research around the world, across our nation and within the NIH. The AIDS Policy Project identified that the NIH had trouble tracking AIDS cure research, in part, because it had no code to do so. It does now. It has been suggested that advocacy efforts include appealing to the Office of AIDS Research, led by Jack Whitescarver, PhD, at the NIH, to better follow the arc of AIDS cure research and that an annual report should be issued highlighting progress toward a cure.

We need the United States’ National HIV/AIDS Strategy to more clearly spell out a plan for AIDS cure research. And to encourage its stewards to ensure that that happens. We need to educate members of the U.S. House of Representatives and the Senate about AIDS cure research so they will fund it properly.

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, recently announced a NIAID research grant named in honor of legendary treatment activist Martin Delaney. The grant allocates $8.5 million a year for five years to search for a functional cure. Sean Strub, POZ’s founder, said in response to the grant, “If Pharma [sic], the public health establishment and AIDS service organizations lobbied for funding for cure research the way they lobby (directly and indirectly) for ‘routinizing’ testing, PrEP, ‘Test and Treat,’ etc., this would be $8.5 billion rather than $8.5 million. “

Referencing the power of lobbyists for AIDS vaccine research, Françoise Barré-Sinoussi (who codiscovered HIV) said, “There is no equivalent for research into remission or [a] functional cure [for AIDS].”  Barré-Sinoussi, who will head the International AIDS Society beginning in 2012, led a two-day workshop on the cure just before the IAC in Vienna.

Thanks to pressure from advocates like the folks at the AIDS Policy Project and others, the tide may be beginning to turn. On August 31, Carl Dieffenbach, PhD, director of AIDS at NIAID, announced in a conference call with activists that “AIDS cure research” would be one of the top four NIH priorities next year. It is up to us to keep the heat on that promise.

Accelerating the cure for AIDS will require more attention; more money; more, and new kinds of research; greater determination—and people living with HIV who are willing to enroll in pilot studies. Because while mice are nice, the fastest way to get to an actionable cure for AIDS is to test potential therapies, when proven safe, as quickly as possible in people living with the virus.

Of all the things we need to do to hasten the end of AIDS, we need to not be afraid to dream of the cure and to say it out loud. Because when it comes to the cure for AIDS, we’ve already seen that it doesn’t pay to be quiet as a mouse.

Pages: 1 | 2 | 3 | 4

Search: cure, research, AIDS, advocacy, antiretrovirals, ARV, UNAIDS, Ryan White CARE Act, ADAP, amfAR, IAC, Kevin Frost, AIDS Policy Project, Kate Krauss, Paula Cannon, protease, vaccine, NIH, PrEP, leukemia, CCR5, Berlin, Martin Delaney, Anthony Fauci, Sean Strub, Francoise Barre-Sinoussi, zinc-finger nucleases, ZFN, CD4, RNA, CD-1, DermaVir, Merck, cell-based, genetic therapies, Sangamo BioSciences, Paula Cannon, CD8 cells, Genetic Immunity, HDAC, ERAMUNE


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 11 (of 11 total)    

Mark, Toronto, 2012-03-10 12:43:47
After 22 years I have yet to see any evidence that Pharma's could block a cure even if they wanted to. The fact remains HIV is complex and wily, and our science is just not quite there yet. But its easier to blame the invisible man behind the curtain.

Berry, Amsterdam, 2011-05-09 06:40:42
I loved this articale. I am some one who has probably been infected with HIV(have to wait 2 more months on the outcome) Now I know there realy is hope of finding a cure

vc, , 2011-03-21 15:43:49
I'm sure as hell in times of wikileaks the big pharmas couldn't hide a cure, but i can't answer in terms of pharmas slowing down the process. i'm also sure about that pharmas will have an occupation.

papilword, atlanta, 2011-03-11 16:10:57
such an interesting article. but should the next article/poz cover be about conspiracy theories and if they're true or not? for every person who gives positive information about a cure, there is another who says pharmacies are in control. is this true? should we believe this when so many are suffering. it scares me to think that a cure would be witheld because of pharma or gov. is making money. can anyone help me with these questions?

ethanwilson, Nashville, 2011-03-02 01:02:20
I am a fan of Ms. Hofmann's writing. And it made my heart sing, to read this brilliant article.Are we going to stand up and fight for a cure, when we are so close? The answer is yes! But we need to do it now,when the berlin patient has shown us the way. More and more, i hear the commom conspiracy theories...i ask...what good is this doing for those who are positive and who are sick? No. We need to direct our energy and commom sense toward the cure now. Please let's take a stand.

James, Winnipeg, 2011-02-22 13:29:22
I truly agree with Harsha. I believe after 20 years of intense research we know enough about HIV. We know plenty. I think a cure could be developed quickly, but these meds are a great safety net for many drug companies. I think it's a crime we don't have a cure yet. We need to stand up and start to stir the porriage.

kenny, Fort Collins, 2010-12-08 14:16:15
The Fact of the matter is that many people will loose their jobs if thier is a cure and that would hurt a lot of people and their neg families Do they really care about the impact on positive people and their families. I think not If they could live the life that people like myself who is raising two children and taking all the meds just to stay healthy they might chage thier minds.But That woin't happen and if their is a cure i would bet my life they would only give it to people who could pay.

Harsha, , 2010-10-27 15:50:26
VEry true, Who knows what the hell s happening on the name of RESEARCH AND CURE OF HIV AND AIDS, I am sure there is cure but the multinational companies wont let it out as they want to earn by selling their meds.... thats all,, or else is there not 1 genius in this world who can find cure to this desease....

Karen W, Sanford, Florida, 2010-10-12 13:01:45
You GO Waldon A.!!! We need patients like you to stand up and show what you want - not bitch about what you do or do not do, have or do not have. I want allof my patients to know they still have LIFE and make something of it. My clinic can;t even get consumer advisory boards to activate. We need people like you - God Bless. Karen W Florida

scott sproat, pacheco, california, 2010-10-09 18:18:07
our government has had a cure for AIDS but they want to weed out gay people first. gay men would have never got infected had it not been for heterosexuals who actually started this epidemic. still today-most heteros NEVER use a damn condom. they continue to blame us gay men for all of it. its a bunch of BS.

Waldon, dc, 2010-10-08 06:06:32
Being a rapid progresser, currently having a spat of good health, I love it when people start talking cure. Most of diseases have walks for the cure. You almost never hear that word when it comes to AIDS. I just won the courage award in the dc aidswalk this year, and am willing to do anything I can to promote funding for a cure!!!! I plan to run a marathon every year, when I can afford it, until there is a cure. My name is Waldon ADAMS,and I have a AIDS diagnosis!! I run for AIDS cures!!

comments 1 - 11 (of 11 total)    

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    usuallyhappy
    Palm Springs
    California


    cortaza100
    Chicago
    Illinois


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.